A detailed history of Strategic Global Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Strategic Global Advisors, LLC holds 93,036 shares of EXEL stock, worth $3.24 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
93,036
Previous 93,957 0.98%
Holding current value
$3.24 Million
Previous $2.11 Million 14.35%
% of portfolio
0.48%
Previous 0.45%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.96 - $27.6 $20,225 - $25,419
-921 Reduced 0.98%
93,036 $2.41 Million
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $36,367 - $42,429
1,788 Added 1.94%
93,957 $2.11 Million
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $1.86 Million - $2.21 Million
92,169 New
92,169 $2.19 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Strategic Global Advisors, LLC Portfolio

Follow Strategic Global Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Global Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Global Advisors, LLC with notifications on news.